Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; DTaP poliovirus vaccine; Measles mumps and rubella virus vaccine; Varicella zoster virus vaccine live
- Indications Diphtheria; Herpes zoster; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 20 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, according to to ClinicalTrials.gov record.
- 11 May 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2015, according to to ClinicalTrials.gov record.